Analysis Of The Clinical Efficacy Of Raltitrexed And Oxaliplatin Combined With Transcatheter Arterial Chemoembolization In Treating Colorecta Cancer Liver Matastases

Objective: To observe the safety and efficacy of raltitrexed and oxaliplatincombined with transcatheter arterial chemoembolization on treatment of colorectacancer liver matastases.Method: Thirty-six case of liver matastases of colorecta cancer patients wereincluded in this study,which used raltitrexed and oxaliplatin regimen for16patientssince May2013were prospectively included in(A group),20cases of the use ofpirarubicin and oxaliplatin regimen as historical control were retrospectively included inthe analysis(group B).Comparison of A,B two groups of patients and objectiveefficiency,benefit rate,toxicity,and to further explore the correlation of liver matastasestumor burden and therapeutic effect.Results: The objective efficiency was78.6%（11/16）,and the benefit rate was87.5%（14/16）in group A,while they were25%（5/20）and50%（10/20）in group Bwith significant statistics differences(2=6.891，P=0.009；2=5.625， P=0.044）.The quality of life was improved in4patients and stable in8of group A,while no patientswas improved and8were stable in group B(2=7.650， P=0.022).There was asignificantly negative correlation between the tumor burden and therapeutic effect（Kendall r=-0.760，P=0.001；Spearman r=-0.811，P＜0.001）.Conclusion: Raltitrexed and oxaliplatin combined with transcatheter arterialchemoembolization is a safe,effective treatment method in treating colorecta cancerliver matastases.